Bio News
U.S.-based IntraBio has expanded the indications for Aqneursa. The U.S. Food and Drug Administration (FDA) approved Aqneursa for the first time as a treatment for ataxia-telangiectasia (A-T). IntraBio confirmed symptom improvement compared with placebo in a phase 3 trial involving 73 patients.
BIOBOOK TEAM
biobookmedia@biobook.co.krIpscell Receives Notice of Allowance for Universal iPSC Patent, Strengthening Cell Line Supply Business
Ministry of Trade, Industry and Energy and Ministry of Food and Drug Safety Sign Agreement on AI Transformation and Global Competitiveness in Biotech
Paragon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
